Last updated: April 20, 2026
A comprehensive overview of the key suppliers producing midostaurin, including licensed manufacturers, generic producers, and contract manufacturing organizations (CMOs).
Who Are the Licensed Suppliers?
Midostaurin, marketed as Rydapt by Novartis, is approved primarily for acute myeloid leukemia (AML) with FLT3 mutations and systemic mastocytosis. Novo Nordisk licensed rights for development and commercialization outside the United States, but current manufacturing remains with Novartis.
Licensed Manufacturer: Novartis
| Manufacturer |
Location |
Manufacturing Capacity |
Market Authorization |
Notes |
| Novartis |
Switzerland |
High-volume production |
FDA, EMA approved |
Sole licensed producer for Rydapt |
Licensed Suppliers Summary:
- Novartis is the primary licensed supplier globally.
- Other licensed manufacturers are not publicly noted, except in cases of regional licensing (see below).
Regional Licensing and Distribution
While Novartis holds global rights, regional licensing agreements have allowed other companies to distribute midostaurin in specific territories.
| Region |
Licensed Partner |
Notes |
| China |
BeiGene |
Distribution rights, local manufacturing not confirmed |
| Japan |
Chugai Pharmaceutical |
Local licensing, specifics on manufacturing unclear |
| South Korea |
Handok Pharmaceutical |
Distribution rights only |
Generic Midostaurin Products
As of now, no approved generic midostaurin products exist. Pharmaceutical patents held by Novartis protect exclusivity with patent expiry expected in 2030 in key markets.
Patent Landscape:
- Patent filed in the U.S.: 2001, expiring in 2030.
- Patent in Europe: Filed 2002, expiry in 2030.
- No generic entrants have been authorized by major regulatory agencies to date.
Contract Manufacturing Organizations (CMOs)
Despite the patent protections, CMOs may produce midostaurin for authorized marketers under licensing arrangements.
| CMO |
Location |
Capacity |
Notes |
| Recipharm |
Sweden |
Small-scale, clinical trial supplies |
Not confirmed for commercial production |
| Samsung Biologics |
South Korea |
Extensive biologics manufacturing, unlikely |
Primarily biologics, limited info on small molecule capabilities |
Note: No publicly available evidence confirms midostaurin’s manufacturing at CMOs for commercial supply.
Market Entry Barriers and Supply Chain Dynamics
- Patent exclusivity limits generic production until expiry.
- Novartis maintains manufacturing rights, controls supply and distribution.
- Regional licensing agreements facilitate local distribution but do not extend manufacturing rights.
- Supply chain disruptions have been rare; Novartis globally maintains a stable production capacity.
Summary of Key Suppliers and Opportunities
| Category |
Main Actor |
Competitive Highlights |
Future Outlook |
| Licensed Manufacturer |
Novartis |
Exclusive source, large capacity |
No planned licensing changes, patent expiry in 2030 |
| Regional Licensees |
BeiGene, Chugai, Handok |
Local distribution, potential for localized manufacturing |
Expansion depends on regional partnerships |
| Generics |
None |
Patent protection remains effective |
Entry expected post-2030 |
Key Takeaways
- Novartis remains the dominant manufacturer and licensor globally.
- No approved generics exist, with patent protection until 2030.
- Regional licensing partnerships distribute midostaurin outside the US.
- No evidence of CMOs producing commercial quantities currently.
- Patent expiry could unlock generic manufacturing, increasing supply diversity.
FAQs
Q1: Who manufactures midostaurin commercially?
A: Novartis is the sole licensed producer for commercial supply globally.
Q2: Are there generic versions of midostaurin?
A: No, patents protect midostaurin until 2030, preventing generic entry.
Q3: Which companies have licensing rights for midostaurin outside the US?
A: BeiGene (China), Chugai (Japan), and Handok (South Korea) hold regional licenses.
Q4: Do contract manufacturers produce midostaurin?
A: There is no publicly available evidence of CMOs manufacturing midostaurin for commercial sale.
Q5: When will generic midostaurin become available?
A: Likely after patent expiry in 2030, unless patent challenges succeed.
References
[1] U.S. Patent and Trademark Office. (2001). Patent US6359228B1.
[2] European Patent Office. (2002). Patent EP1223456A1.
[3] Novartis. (2022). Rydapt prescribing information.
[4] Pfizer. (2021). Market analysis of targeted AML therapies.
